Alto Neuroscience Inc. (ANRO)
NYSE
Closed
Aug 24, 2026
Day's Range
33.9152 wk Range
3.41Profile - ANRO - Alto Neuroscience Inc.
Profile
Mic Code
XNYS
Sector
Healthcare
Industry
Biotechnology
Employees
68
Alto Neuroscience Inc. is a biotechnology company that focuses on developing precision therapeutics for psychiatric disorders. The company's primary objective is to utilize advanced neurobiological insights and digital tools to tailor treatments for conditions like depression, anxiety, and other mental health disorders. Utilizing cutting-edge techniques such as AI-driven patient profiling and biomarker-based approaches, Alto Neuroscience seeks to enhance the efficacy of mental health treatments by ensuring more personalized and targeted solutions. This approach represents a significant innovation in the mental health sector by moving away from the one-size-fits-all model of psychotropic medications. In terms of market impact, Alto Neuroscience operates at the intersection of biotechnology and digital health, playing a pivotal role in the evolution of psychiatric treatment paradigms. The company's efforts contribute to the broader healthcare landscape by potentially improving patient outcomes and reducing trial and error in mental health medication management.
Profile Details
Type
Common Stock
Ceo
Dr. Amit Etkin M.D., Ph.D.
Address
650 Castro Street
City
Mountain View
State
CA
Zip
94041
Country
United States
Phone
650 200 0412
Key Executives - ANRO - Alto Neuroscience Inc.
Key executives
Cross Listings - ANRO - Alto Neuroscience Inc.
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
